As for the overall survival of the GC/GEJC patients, in Yoon et al. [15] and Yoshikawa et al. [17], the application of RAM to mFOLFOX6 combination and S-1+oxaliplatin did not significantly extend the patients' median OS (Table 1). Here, PSMD1 is linked to gastric cancer.